Bank of America Raises Price Target on Hims & Hers Health Amid FDA Move on Wellness Peptides
Bank of America raised its price target on Hims & Hers Health (HIMS) to $25 from $21, citing the FDA's procedural step toward evaluating wellness peptides, which could open new revenue streams. The move allows Hims & Hers to potentially repurpose its GLP-1 manufacturing capacity, though the Neutral rating indicates a balanced risk-reward assessment at current levels.
Topics: analyst upgrade FDA approval pharmaceuticals price target revenue potential